NCT06757595

Brief Summary

To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
7 years until next milestone

First Submitted

Initial submission to the registry

December 25, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 25, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 25, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 3, 2025

Completed
Last Updated

January 3, 2025

Status Verified

November 1, 2024

Enrollment Period

7 years

First QC Date

December 25, 2024

Last Update Submit

January 2, 2025

Conditions

Keywords

Retinal Vein Occlusionclinical featuretherapy

Outcome Measures

Primary Outcomes (1)

  • Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response

    Age, gender, blood routine (platelet count, neutrophil count, monocyte count, and lymphocyte count), four coagulation tests (prothrombin time determination, activated partial thromboplastin time determination), blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein data), hypertension, diabetes, coronary heart disease, and cerebral infarction were collected in detail Death history, laser, anti-VEGF injection, hormone and other treatment methods and times, and the visual acuity at the last follow-up. The general conditions of the patients were statistically analyzed, such as the proportion of previous history of hypertension and diabetes, and the mean value of blood lipids, blood clotting images and other blood test results of the patients were calculated, and the correlation between them and the prognosis of vision was analyzed.

    From January 2024 to January 2025

Study Arms (2)

rvo patients

Initial onset and meeting the diagnostic criteria for RVO (including BRVO and CRVO)

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with RVO diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University from January 2018 to December 2024 were enrolled

You may qualify if:

  • meeting the diagnostic criteria for RVO (including BRVO and CRVO)

You may not qualify if:

  • patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
  • patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
  • patients with incomplete clinical data and information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

Location

MeSH Terms

Conditions

Retinal Vein Occlusion

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesVenous ThrombosisThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 25, 2024

First Posted

January 3, 2025

Study Start

January 1, 2018

Primary Completion

December 25, 2024

Study Completion

December 25, 2024

Last Updated

January 3, 2025

Record last verified: 2024-11

Locations